中东呼吸综合征冠状病毒刺突蛋白：疫苗和治疗方法的靶点。
MERS-CoV spike protein: Targets for vaccines and therapeutics.
作者信息
Wang Qihui, Wong Gary, Lu Guangwen, Yan Jinghua, Gao George F
机构信息
CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Shenzhen 518112, China.
Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Shenzhen 518112, China; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; CAS Center for Influenza Research and Early-warning (CASCIRE), Chinese Academy of Sciences, Beijing 100101, China.
出版信息
Antiviral Res. 2016 Sep;133:165-77. doi: 10.1016/j.antiviral.2016.07.015. Epub 2016 Jul 26.
The disease outbreak caused by Middle East respiratory syndrome coronavirus (MERS-CoV) is still ongoing in the Middle East. Over 1700 people have been infected since it was first reported in September 2012. Despite great efforts, licensed vaccines or therapeutics against MERS-CoV remain unavailable. The MERS-CoV spike (S) protein is an important viral antigen known to mediate host-receptor binding and virus entry, as well as induce robust humoral and cell-mediated responses in humans during infection. In this review, we highlight the importance of the S protein in the MERS-CoV life cycle, summarize recent advances in the development of vaccines and therapeutics based on the S protein, and discuss strategies that can be explored to develop new medical countermeasures against MERS-CoV.
中东呼吸综合征冠状病毒（MERS-CoV）引发的疾病疫情仍在中东地区持续。自2012年9月首次报告以来，已有超过1700人受到感染。尽管付出了巨大努力，但针对MERS-CoV的许可疫苗或治疗方法仍然无法获得。MERS-CoV刺突（S）蛋白是一种重要的病毒抗原，已知其介导宿主受体结合和病毒进入，并且在感染期间可在人体内诱导强烈的体液免疫和细胞介导免疫反应。在本综述中，我们强调了S蛋白在MERS-CoV生命周期中的重要性，总结了基于S蛋白的疫苗和治疗方法开发的最新进展，并讨论了可探索的针对MERS-CoV开发新的医学应对措施的策略。
Zotero 插件